Top 100 medical and healthcare startups in USA
Apr 16, 2026
|
Like
19
1
Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
2
Funding: $22M
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
3
Funding: $287M
Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions.
Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions.
4
Funding: $141M
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.
5
Funding: $93.9M
Adonis is a revenue intelligence and automation platform built for healthcare that improve critical RCM outcomes.
Adonis is a revenue intelligence and automation platform built for healthcare that improve critical RCM outcomes.
6
Funding: $89.6M
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. The company has built a proprietary platform that integrates emerging AI technologies with physics-based simulations to rationally design and optimize peptide therapeutics. Its initial focus is on immunology and cardiometabolic indications.
7
Funding: $2M
SpendRule, a contract intelligence platform, makes contracts the first line of defense against overpayments.
SpendRule, a contract intelligence platform, makes contracts the first line of defense against overpayments.
8
Funding: $407M
Science Corp creates PRIMA retinal implant that has demonstrated in clinical trials the ability to restore vision to patients blinded by the effects of dry advanced macular degeneration. It's a chip said to be smaller than a grain of rice that, when implanted in the eye, works with camera-equipped glasses to restore functional vision. In trials spanning 47 patients across Europe and the U.S., 80% demonstrated meaningful improvement in visual acuity and were able to read letters, numbers, and words, the company says.
Science Corp creates PRIMA retinal implant that has demonstrated in clinical trials the ability to restore vision to patients blinded by the effects of dry advanced macular degeneration. It's a chip said to be smaller than a grain of rice that, when implanted in the eye, works with camera-equipped glasses to restore functional vision. In trials spanning 47 patients across Europe and the U.S., 80% demonstrated meaningful improvement in visual acuity and were able to read letters, numbers, and words, the company says.
9
Funding: $203.1M
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
EpiBiologics is advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins pipeline of novel bispecific antibodies. It's main candidate EPI-326 for treatment of EGFR-driven lung cancer and head and neck cancer is in the clinical trial phase. It is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localising degradation to the tumour while sparing normal healthy tissue. In preclinical studies, EPI-326 showed its strong and durable efficacy with favourable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.
10
Funding: $200M
AirNexis has exclusive rights to develop AN01- drug for chronic obstructive pulmonary disease (COPD) outside of China from Haisco Pharmaceutical Group. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors.
AirNexis has exclusive rights to develop AN01- drug for chronic obstructive pulmonary disease (COPD) outside of China from Haisco Pharmaceutical Group. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors.
11
Funding: $180M
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
12
Funding: $146.5M
CancerVax is developing a new bispecific antibody vaccine for the treatment of recurrent Ewing sarcoma. This therapeutic vaccine can target and attach to Ewing sarcoma cancer cells, recruiting the body's natural killer T cells to the tumor to destroy it; hence the name "bispecific." In extensive laboratory cell studies, several candidates demonstrated significant T-cell killing of Ewing sarcoma cells, meaning the vaccine was doing its job of recruiting T cells to the tumor cells for destruction. The company also has candidates for the treatment of pancreatic and liver cancer.
CancerVax is developing a new bispecific antibody vaccine for the treatment of recurrent Ewing sarcoma. This therapeutic vaccine can target and attach to Ewing sarcoma cancer cells, recruiting the body's natural killer T cells to the tumor to destroy it; hence the name "bispecific." In extensive laboratory cell studies, several candidates demonstrated significant T-cell killing of Ewing sarcoma cells, meaning the vaccine was doing its job of recruiting T cells to the tumor cells for destruction. The company also has candidates for the treatment of pancreatic and liver cancer.
13
Funding: $125M
Ambros was created to test and market neridronate, a drug designed to reduce pain in complex regional pain syndrome type 1, in North America. The startup acquired the rights to this drug from the Italian company Abiogen (the drug is approved in Italy). CRPS-1, formerly known as reflex sympathetic dystrophy, is a rare disorder characterized by intense and sometimes continuous pain in the affected limb following a bone injury.
Ambros was created to test and market neridronate, a drug designed to reduce pain in complex regional pain syndrome type 1, in North America. The startup acquired the rights to this drug from the Italian company Abiogen (the drug is approved in Italy). CRPS-1, formerly known as reflex sympathetic dystrophy, is a rare disorder characterized by intense and sometimes continuous pain in the affected limb following a bone injury.
14
Funding: $112.5M
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
15
Funding: $75M
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations - namely viral respiratory infections, starting with rhinovirus, the most common respiratory virus on the planet.
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations - namely viral respiratory infections, starting with rhinovirus, the most common respiratory virus on the planet.
16
Funding: $60M
Thesis offers AI agents within healthcare to assist with clinical operations and care management.
Thesis offers AI agents within healthcare to assist with clinical operations and care management.
17
Funding: $28.6M
Somethings is a platform for wellness tailored to young people that links youngsters with qualified mentors.
Somethings is a platform for wellness tailored to young people that links youngsters with qualified mentors.
18
Funding: $21M
Oryon develops cell therapies for Parkinson's disease by targeting dopamine production. Most current treatments rely on neuronal progenitor cells, which are implanted into the brain, where they proliferate and eventually become A9 neurons - the primary dopamine-producing cells that degenerate in Parkinson's patients, causing the disease's motor symptoms. In contrast, Oryon implants fully developed A9 neurons from the start, aiming to more directly restore dopamine production. Another key difference is its unilateral approach: the company treats only one side of the brain, while most competing programs utilize bilateral treatment. The company's lead program is in clinical trials and has shown improvement in motor function, as well as neuroimaging data indicating restoration of dopaminergic signaling in the transplanted brain region.
Oryon develops cell therapies for Parkinson's disease by targeting dopamine production. Most current treatments rely on neuronal progenitor cells, which are implanted into the brain, where they proliferate and eventually become A9 neurons - the primary dopamine-producing cells that degenerate in Parkinson's patients, causing the disease's motor symptoms. In contrast, Oryon implants fully developed A9 neurons from the start, aiming to more directly restore dopamine production. Another key difference is its unilateral approach: the company treats only one side of the brain, while most competing programs utilize bilateral treatment. The company's lead program is in clinical trials and has shown improvement in motor function, as well as neuroimaging data indicating restoration of dopaminergic signaling in the transplanted brain region.
19
Funding: $16.2M
Lin is an online pain management platform offering personalized, evidence-based programs from experts. It matches patients with chronic pain with personalized pain recovery consultant to create a customized treatment plan. The consultant guides them throughout the program and multidisciplinary clinical team provides oversight. Although the platform uses artificial intelligence to scale, all care is provided by humans. Treatments are not medication-based, but rather brain-focused techniques and physical therapy. The company partners with healthcare providers and insurance companies to offer patients evidence-based, low-risk chronic pain treatments.
Lin is an online pain management platform offering personalized, evidence-based programs from experts. It matches patients with chronic pain with personalized pain recovery consultant to create a customized treatment plan. The consultant guides them throughout the program and multidisciplinary clinical team provides oversight. Although the platform uses artificial intelligence to scale, all care is provided by humans. Treatments are not medication-based, but rather brain-focused techniques and physical therapy. The company partners with healthcare providers and insurance companies to offer patients evidence-based, low-risk chronic pain treatments.
20
Funding: $3.8B
Verily Health is Alphabet's life science subsidiary, that works at the intersection of healthcare, research and technology and focuses on using AI for precision medicine. The company develops tools and platforms for disease prevention, diagnosis and management.
Verily Health is Alphabet's life science subsidiary, that works at the intersection of healthcare, research and technology and focuses on using AI for precision medicine. The company develops tools and platforms for disease prevention, diagnosis and management.
21
Funding: $2.4B
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
Arrowhead Research has created the Arrowhead TRiM drug discovery and development platform that utilizes a suite of RNA interference (RNAi) delivery technologies, chemistry, structures, and manufacturing technologies. REDEMPLO (plozasiran) is the company's lead (FDA-approved) siRNA-based drug used to significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). Arrowhead is also conducting clinical trials for drugs against coronary artery disease, atherosclerotic cardiovascular disease, obesity, COPD, idiopathic pulmonary fibrosis, Alzheimer's disease, Huntington's disease, alpha-1 antitrypsin deficiency and hepatitis B.
22
Funding: $312.1M
Eight Sleep is a sleep fitness company that leverages personal biometrics to restore individuals to their peak energy levels each morning.
Eight Sleep is a sleep fitness company that leverages personal biometrics to restore individuals to their peak energy levels each morning.
23
Funding: $219.3M
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
24
Funding: $204M
Solace Health creates healthcare navigation platform that connects patients with experienced expert advocates via phone, text or email. The experts help navigate the care process, whether it's receiving a new diagnosis, finding a doctor, coordinating treatment, obtaining authorizations or managing a chronic condition. The service is covered by Medicare, most Medicare Advantage plans and some insurance companies. The company partners with healthcare providers and offers its own electronic health record card for updates and expert's access to patient medical records to assist with the navigation process.
Solace Health creates healthcare navigation platform that connects patients with experienced expert advocates via phone, text or email. The experts help navigate the care process, whether it's receiving a new diagnosis, finding a doctor, coordinating treatment, obtaining authorizations or managing a chronic condition. The service is covered by Medicare, most Medicare Advantage plans and some insurance companies. The company partners with healthcare providers and offers its own electronic health record card for updates and expert's access to patient medical records to assist with the navigation process.
25
Funding: $160M
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
26
Funding: $124M
Sage is an app helps to improve care with better caregiver tools that ensures older adults receive individual care.
Sage is an app helps to improve care with better caregiver tools that ensures older adults receive individual care.
27
Funding: $110.3M
Crossbow Therapeutics develops antibody therapeutics to treat cancer. It identifies, validates and prioritizes the most promising cancer antigens for its T-Cell Receptor mimetic (TCRm) discovery efforts. Its lead candidate is T-cell engager CBX-250, designed to target a peptide human leukocyte antigen (pHLA) that’s found on myeloid cancer cells. The company is conducting trials which have enrolled patients with acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Crossbow also develops other so-called T-Bolt immunotherapies, which use TCR-mimetic antibodies to target pHLA on cancer cells.
Crossbow Therapeutics develops antibody therapeutics to treat cancer. It identifies, validates and prioritizes the most promising cancer antigens for its T-Cell Receptor mimetic (TCRm) discovery efforts. Its lead candidate is T-cell engager CBX-250, designed to target a peptide human leukocyte antigen (pHLA) that’s found on myeloid cancer cells. The company is conducting trials which have enrolled patients with acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia. Crossbow also develops other so-called T-Bolt immunotherapies, which use TCR-mimetic antibodies to target pHLA on cancer cells.
28
Funding: $109M
Neomorph develops "molecular glue" technology for binding drugs to tumor cell proteins and degrading these proteins to treat so far inaccessible targets. The company's degraders redirect cellular mechanisms known as E3 ubiquitin ligases to disease-causing proteins, leading to their degradation. This targeted protein degradation destroys the target protein by the 26S proteasome, thereby eliminating all associated biological activity. While heterobifunctional drugs still require a binding pocket on the target protein, "molecular glue" drugs bypass this requirement, thus offering a differentiated approach to drug development with different rules and the potential to target a broad spectrum of the proteome. The company is currently conducting clinical trials of its technology for the treatment of renal cell carcinoma.
Neomorph develops "molecular glue" technology for binding drugs to tumor cell proteins and degrading these proteins to treat so far inaccessible targets. The company's degraders redirect cellular mechanisms known as E3 ubiquitin ligases to disease-causing proteins, leading to their degradation. This targeted protein degradation destroys the target protein by the 26S proteasome, thereby eliminating all associated biological activity. While heterobifunctional drugs still require a binding pocket on the target protein, "molecular glue" drugs bypass this requirement, thus offering a differentiated approach to drug development with different rules and the potential to target a broad spectrum of the proteome. The company is currently conducting clinical trials of its technology for the treatment of renal cell carcinoma.
29
Funding: $95.3M
Turquoise Health is a health tech company that simplifies administration to reduce the expense and complexity of healthcare.
Turquoise Health is a health tech company that simplifies administration to reduce the expense and complexity of healthcare.
30
Funding: $72M
Link Cell Therapies develops CAR-T cell therapies for patients with solid tumors. The company has developed unique AND gate technology that requires co-expression of cancer targets to ensure cellular cytotoxicity and greater tumor specificity. It enables safe targeting of multiple antigens that are co-expressed on cancer cells but have no or minimal overlap in normal healthy tissue. Combined with additional platforms in development, the company is advancing number of promising therapeutic programs that promise to unlock the potential of CAR T therapy in a variety of important oncological diseases, including solid tumors and certain hematological malignancies. Johnson & Johnson is a major investor in the startup.
Link Cell Therapies develops CAR-T cell therapies for patients with solid tumors. The company has developed unique AND gate technology that requires co-expression of cancer targets to ensure cellular cytotoxicity and greater tumor specificity. It enables safe targeting of multiple antigens that are co-expressed on cancer cells but have no or minimal overlap in normal healthy tissue. Combined with additional platforms in development, the company is advancing number of promising therapeutic programs that promise to unlock the potential of CAR T therapy in a variety of important oncological diseases, including solid tumors and certain hematological malignancies. Johnson & Johnson is a major investor in the startup.
31
Funding: $51.9M
DermaSensor is developing a handheld device for practitioners for detection of skin cancer risk. It is the first FDA-cleared AI-powered skin cancer diagnostic device that enables objective referral prioritization using a 0-10 cancer risk assessment scale. A total of five spectral data points are captured from each skin lesion. The DermaSensor algorithm analyzes the spectral data and provides a skin cancer risk assessment in seconds. The tip of the device reflects and records short bursts of light from the lesion's cellular and subcellular contents. The light is analyzed by a built-in computer, providing information that helps physicians evaluate skin lesions (including melanomas, squamous cell carcinomas and basal cell carcinomas) to determine referral.
DermaSensor is developing a handheld device for practitioners for detection of skin cancer risk. It is the first FDA-cleared AI-powered skin cancer diagnostic device that enables objective referral prioritization using a 0-10 cancer risk assessment scale. A total of five spectral data points are captured from each skin lesion. The DermaSensor algorithm analyzes the spectral data and provides a skin cancer risk assessment in seconds. The tip of the device reflects and records short bursts of light from the lesion's cellular and subcellular contents. The light is analyzed by a built-in computer, providing information that helps physicians evaluate skin lesions (including melanomas, squamous cell carcinomas and basal cell carcinomas) to determine referral.
32
Funding: $31.6M
Nadia Care is a maternal health company dedicated to supporting moms throughout their pregnancy and after their baby is born.
Nadia Care is a maternal health company dedicated to supporting moms throughout their pregnancy and after their baby is born.
33
Funding: $5.7M
Flourish Care is a maternal healthcare center that offers childbirth education, birth plans, and newborn care services.
Flourish Care is a maternal healthcare center that offers childbirth education, birth plans, and newborn care services.
34
Funding: $578.8M
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver and kidney tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
HistoSonics has developed Edison - noninvasive ultrasound therapy platform, which utilizes histotripsy to destroy target liver and kidney tumors at the subcellular level. This is a form of focused ultrasound utilizes high-amplitude, very short pulses to create a "bubble cloud" designed to mechanically disrupt and liquefy target liver tumors. These bubble clouds form and collapse in microseconds, generating mechanical forces strong enough to destroy tissue at the cellular and subcellular levels in a noninvasive and nonthermal manner. The Edison device provides continuous imaging, personalized treatment and physician guidance. Acquired by K5 Global
35
Funding: $496.4M
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
36
Funding: $440.1M
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
37
Funding: $352M
Enable Injections produces wearable delivery devices for injectible drugs. The Enable Injections products can deliver drugs directly from standard vials supplied by all pharmaceutical companies, can reconstitute powdered drugs into liquids as a part of the injection procedure, can inject very viscous drugs, and can inject up to 20 ml. Such products are called bolus injection systems.
Enable Injections produces wearable delivery devices for injectible drugs. The Enable Injections products can deliver drugs directly from standard vials supplied by all pharmaceutical companies, can reconstitute powdered drugs into liquids as a part of the injection procedure, can inject very viscous drugs, and can inject up to 20 ml. Such products are called bolus injection systems.
38
Funding: $328M
Grow Therapy helps therapists easily start and grow thriving insurance-accepting practices, giving them the administrative and business tools, peer community support, and pipeline of referrals they need to make their lives better.
Grow Therapy helps therapists easily start and grow thriving insurance-accepting practices, giving them the administrative and business tools, peer community support, and pipeline of referrals they need to make their lives better.
39
Funding: $204M
Solace is a digital health platform that connects patients with professional health advocates.
Solace is a digital health platform that connects patients with professional health advocates.
40
Funding: $182.3M
Actuate Therapeutics develops molecular drugs for cancer treatment. Its lead drug, elraglusib (a GSK-3 inhibitor), targets multiple molecular pathways in cancer cells involved in promoting tumor growth and developing resistance to traditional anticancer drugs and chemotherapy. Elraglusib is also considered a mediator of antitumor immunity by inhibiting multiple immune checkpoints and regulating immune cell function. Actuate has demonstrated promising results in the treatment of pancreatic cancer, childhood malignancies, metastatic salivary gland carcinoma and melanoma.
Actuate Therapeutics develops molecular drugs for cancer treatment. Its lead drug, elraglusib (a GSK-3 inhibitor), targets multiple molecular pathways in cancer cells involved in promoting tumor growth and developing resistance to traditional anticancer drugs and chemotherapy. Elraglusib is also considered a mediator of antitumor immunity by inhibiting multiple immune checkpoints and regulating immune cell function. Actuate has demonstrated promising results in the treatment of pancreatic cancer, childhood malignancies, metastatic salivary gland carcinoma and melanoma.
41
Funding: $137M
Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
42
Funding: $113M
VieCure develops Halo Intelligence - AI-powered software for oncology care. It provides physicians with a clinical analytics system and an electronic medical record for oncology patients, enabling them to develop personalized treatment plans. The platform integrates real-time clinical decision support, practice operating system, codified curated knowledge base, physician mobile app, teleoncology, patient mobile app and AI-powered analytics system.
VieCure develops Halo Intelligence - AI-powered software for oncology care. It provides physicians with a clinical analytics system and an electronic medical record for oncology patients, enabling them to develop personalized treatment plans. The platform integrates real-time clinical decision support, practice operating system, codified curated knowledge base, physician mobile app, teleoncology, patient mobile app and AI-powered analytics system.
43
Funding: $41.7M
DocDelta helps companies in the healthcare ecosystem find and connect with the healthcare institutions and contacts that are most important to them. Marketing, recruiting and sales teams at healthcare services, medical technology companies, hospitals and medical groups trust DocDelta to help them identify and close new business opportunities with personalized conversations at the right time.
DocDelta helps companies in the healthcare ecosystem find and connect with the healthcare institutions and contacts that are most important to them. Marketing, recruiting and sales teams at healthcare services, medical technology companies, hospitals and medical groups trust DocDelta to help them identify and close new business opportunities with personalized conversations at the right time.
44
Funding: $31.3M
WearLinq produces wearable devices for health monitoring and diagnostics, in particular wireless 6-lead clinical ECG monitor and monitor eWave. It pairs with user's phone, transmitting real-time data and reports for up to 48 hours to doctors. The company claims the wireless monitor can last more than five days on a single charge. The device can help detect arrhythmias, but the company plans to expand its use in the future. WearLinq already received FDA clearance for the device to continuously monitor cardiac activity in individuals who may be asymptomatic or experience transient symptoms such as syncope, palpitations, dizziness, shortness of breath, lightheadedness, weakness, fatigue or anxiety.
WearLinq produces wearable devices for health monitoring and diagnostics, in particular wireless 6-lead clinical ECG monitor and monitor eWave. It pairs with user's phone, transmitting real-time data and reports for up to 48 hours to doctors. The company claims the wireless monitor can last more than five days on a single charge. The device can help detect arrhythmias, but the company plans to expand its use in the future. WearLinq already received FDA clearance for the device to continuously monitor cardiac activity in individuals who may be asymptomatic or experience transient symptoms such as syncope, palpitations, dizziness, shortness of breath, lightheadedness, weakness, fatigue or anxiety.
45
Funding: $22M
Salvo Health offers a virtual clinic geared toward people with chronic gut problems, including irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), dyspepsia and small intestinal bacterial overgrowth (SIBO).
Salvo Health offers a virtual clinic geared toward people with chronic gut problems, including irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), dyspepsia and small intestinal bacterial overgrowth (SIBO).
46
Funding: $15.2M
BioVaxys develops immunotherapeutic cancer vaccines targeting lymphoma and ovarian cancer. The company develops them using its proprietary DPX delivery platform. Unlike conventional emulsions or lipid nanoparticles that release their contents systemically, DPX is fully synthetic and compatible with peptides, proteins, mRNA, virus-like particles and small molecules. It is ideal for mRNA delivery, remaining localized at the injection site with superior stability compared to LDL. Maveropepimute-S, the company's lead clinical drug based on this platform, demonstrated an overall response rate of 21% and a disease control rate of 63% in recurrent ovarian cancer. In relapsed/refractory DLBL, the combination of MVP-S and Keytruda achieved complete remission in 3 of 6 evaluable patients. This means that no detectable cancer cells remained after treatment.
BioVaxys develops immunotherapeutic cancer vaccines targeting lymphoma and ovarian cancer. The company develops them using its proprietary DPX delivery platform. Unlike conventional emulsions or lipid nanoparticles that release their contents systemically, DPX is fully synthetic and compatible with peptides, proteins, mRNA, virus-like particles and small molecules. It is ideal for mRNA delivery, remaining localized at the injection site with superior stability compared to LDL. Maveropepimute-S, the company's lead clinical drug based on this platform, demonstrated an overall response rate of 21% and a disease control rate of 63% in recurrent ovarian cancer. In relapsed/refractory DLBL, the combination of MVP-S and Keytruda achieved complete remission in 3 of 6 evaluable patients. This means that no detectable cancer cells remained after treatment.
47
Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
48
Funding: $3.4B
Genetix Biotherapeutics (formerly Bluebird Bio) develops gene therapies for rare genetic diseases using patient's own blood stem cells. The cells are harvested, modified outside the body to add working copies of the affected gene and then reintroduced into the patient, restoring the function of the affected gene. The company specializes in the treatment of sickle cell anemia, beta thalassemia and cerebral adrenoleukodystrophy (CALD). Its unique, single-dose treatments are FDA approved and address the underlying cause of the disease and can provide significant, long-term benefits to patients. Acquired by The Carlyle Group
Genetix Biotherapeutics (formerly Bluebird Bio) develops gene therapies for rare genetic diseases using patient's own blood stem cells. The cells are harvested, modified outside the body to add working copies of the affected gene and then reintroduced into the patient, restoring the function of the affected gene. The company specializes in the treatment of sickle cell anemia, beta thalassemia and cerebral adrenoleukodystrophy (CALD). Its unique, single-dose treatments are FDA approved and address the underlying cause of the disease and can provide significant, long-term benefits to patients. Acquired by The Carlyle Group
49
Funding: $3B
Altos Labs is working on biological reprogramming technology to essentially prolong human life
Altos Labs is working on biological reprogramming technology to essentially prolong human life
50
Funding: $2.8B
Exact Sciences creates noninvasive screening tests for the early detection of cancer. The company's flagship product, Cologuard test, uses a biomarker panel that analyzes a stool sample for 10 DNA markers, as well as fecal blood (hemoglobin). It detects colon cancer even in its early stages, when it is more treatable. The test can be administered at home without special training. Cologuard includes a built-in patient management program with support. The test is based on proprietary QuARTS (quantitative allele-specific amplification of target and real-time signal) technology, which efficiently amplifies and quantifies two distinct methylated DNA markers (NDRG4 and BMP3), as well as seven different point mutations of the KRAS gene. The beta-actin gene (ACTB) serves as a reference marker for quantifying the total amount of human DNA in each sample.
Exact Sciences creates noninvasive screening tests for the early detection of cancer. The company's flagship product, Cologuard test, uses a biomarker panel that analyzes a stool sample for 10 DNA markers, as well as fecal blood (hemoglobin). It detects colon cancer even in its early stages, when it is more treatable. The test can be administered at home without special training. Cologuard includes a built-in patient management program with support. The test is based on proprietary QuARTS (quantitative allele-specific amplification of target and real-time signal) technology, which efficiently amplifies and quantifies two distinct methylated DNA markers (NDRG4 and BMP3), as well as seven different point mutations of the KRAS gene. The beta-actin gene (ACTB) serves as a reference marker for quantifying the total amount of human DNA in each sample.
